Refereed review article in scientific journal (A2)

Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in

List of AuthorsPugliatti Maura, Hartung Hans-Peter, Oreja-Guevara Celia, Pozzilli Carlo, Airas Laura, Alkhawajah Mona, Grigoriadis Nikolaos, Magyari Melinda, Van Wijmeersch Bart, Zakaria Magd, Linker Ralf, Chan Andrew, Vermersch Patrick, Berger Thomas


Publication year2022

JournalFrontiers in Immunology

Journal name in sourceFRONTIERS IN IMMUNOLOGY

Journal acronymFRONT IMMUNOL

Article number 1045101

Volume number13

Number of pages8




Self-archived copy’s web address

It has been over a year since people with multiple sclerosis (pwMS) have been receiving vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). With a negligible number of cases in which vaccination led to a relapse or new onset MS, experts around the world agree that the potential consequences of COVID-19 in pwMS by far outweigh the risks of vaccination. This article reviews the currently available types of anti-SARS-CoV-2 vaccines and the immune responses they elicit in pwMS treated with different DMTs. Findings to date highlight the importance of vaccine timing in relation to DMT dosing to maximize protection, and of encouraging pwMS to get booster doses when offered.

Downloadable publication

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.

Last updated on 2022-14-12 at 14:20